Moderna Ebitda from 2010 to 2024

MRNA Stock  USD 166.61  2.60  1.59%   
Moderna's EBITDA is increasing over the years with stable fluctuation. Overall, EBITDA is projected to go to about -3.1 B this year. From 2010 to 2024 Moderna EBITDA quarterly data regression line had arithmetic mean of  912,675,733 and significance of  0.41. View All Fundamentals
 
EBITDA  
First Reported
2017-12-31
Previous Quarter
300 M
Current Value
-1.2 B
Quarterly Volatility
1.8 B
 
Covid
Check Moderna financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moderna main balance sheet or income statement drivers, such as Interest Expense of 39.9 M, Selling General Administrative of 1.4 B or Total Revenue of 4.9 B, as well as many exotic indicators such as Price To Sales Ratio of 5.34, Dividend Yield of 0.0 or PTB Ratio of 2.61. Moderna financial statements analysis is a perfect complement when working with Moderna Valuation or Volatility modules.
  
This module can also supplement Moderna's financial leverage analysis and stock options assessment as well as various Moderna Technical models . Check out the analysis of Moderna Correlation against competitors.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.

Latest Moderna's Ebitda Growth Pattern

Below is the plot of the Ebitda of Moderna over the last few years. It is Moderna's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moderna's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Pretty Stable
   Ebitda   
       Timeline  

Moderna Ebitda Regression Statistics

Arithmetic Mean912,675,733
Coefficient Of Variation495.97
Mean Deviation2,862,753,138
Median(208,657,000)
Standard Deviation4,526,586,813
Sample Variance20489988.2T
Range16.7B
R-Value0.23
Mean Square Error20921025.3T
R-Squared0.05
Significance0.41
Slope230,577,732
Total Sum of Squares286859834.5T

Moderna Ebitda History

2024-3.1 B
2023-3.2 B
20229.8 B
202113.5 B
2020-731.9 M
2019-514.7 M
2018-388.4 M

About Moderna Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Moderna income statement, its balance sheet, and the statement of cash flows. Moderna investors use historical funamental indicators, such as Moderna's Ebitda, to determine how well the company is positioned to perform in the future. Although Moderna investors may use each financial statement separately, they are all related. The changes in Moderna's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Moderna's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Moderna Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Moderna. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-3.2 B-3.1 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Moderna offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moderna's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moderna Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moderna Stock:
Check out the analysis of Moderna Correlation against competitors.
For information on how to trade Moderna Stock refer to our How to Trade Moderna Stock guide.
You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Complementary Tools for Moderna Stock analysis

When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Fundamental Analysis
View fundamental data based on most recent published financial statements
Equity Valuation
Check real value of public entities based on technical and fundamental data
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.85)
Earnings Share
(15.59)
Revenue Per Share
13.525
Quarterly Revenue Growth
(0.91)
Return On Assets
(0.16)
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moderna is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.